2022-10-062023-03-312023-03-31false14402511CHRISTA GDP PHARMA LTD2023-07-1270229iso4217:GBPxbrli:pure144025112022-10-06144025112023-03-31144025112022-10-062023-03-31144025112022-10-05144025112022-10-05144025112022-10-052022-10-0514402511bus:SmallEntities2022-10-062023-03-3114402511bus:AuditExempt-NoAccountantsReport2022-10-062023-03-3114402511bus:FullAccounts2022-10-062023-03-3114402511bus:PrivateLimitedCompanyLtd2022-10-062023-03-3114402511core:WithinOneYear2023-03-3114402511core:AfterOneYear2023-03-3114402511core:WithinOneYear2022-10-0514402511core:AfterOneYear2022-10-0514402511core:ShareCapital2023-03-3114402511core:SharePremium2023-03-3114402511core:RevaluationReserve2023-03-3114402511core:OtherReservesSubtotal2023-03-3114402511core:RetainedEarningsAccumulatedLosses2023-03-3114402511core:ShareCapital2022-10-0514402511core:SharePremium2022-10-0514402511core:RevaluationReserve2022-10-0514402511core:OtherReservesSubtotal2022-10-0514402511core:RetainedEarningsAccumulatedLosses2022-10-0514402511core:LandBuildings2023-03-3114402511core:PlantMachinery2023-03-3114402511core:Vehicles2023-03-3114402511core:FurnitureFittings2023-03-3114402511core:OfficeEquipment2023-03-3114402511core:NetGoodwill2023-03-3114402511core:IntangibleAssetsOtherThanGoodwill2023-03-3114402511core:ListedExchangeTraded2023-03-3114402511core:UnlistedNon-exchangeTraded2023-03-3114402511core:LandBuildings2022-10-0514402511core:PlantMachinery2022-10-0514402511core:Vehicles2022-10-0514402511core:FurnitureFittings2022-10-0514402511core:OfficeEquipment2022-10-0514402511core:NetGoodwill2022-10-0514402511core:IntangibleAssetsOtherThanGoodwill2022-10-0514402511core:ListedExchangeTraded2022-10-0514402511core:UnlistedNon-exchangeTraded2022-10-0514402511core:LandBuildings2022-10-062023-03-3114402511core:PlantMachinery2022-10-062023-03-3114402511core:Vehicles2022-10-062023-03-3114402511core:FurnitureFittings2022-10-062023-03-3114402511core:OfficeEquipment2022-10-062023-03-3114402511core:NetGoodwill2022-10-062023-03-3114402511core:IntangibleAssetsOtherThanGoodwill2022-10-062023-03-3114402511core:ListedExchangeTraded2022-10-062023-03-3114402511core:UnlistedNon-exchangeTraded2022-10-062023-03-3114402511core:MoreThanFiveYears2022-10-062023-03-3114402511core:Non-currentFinancialInstruments2023-03-3114402511core:Non-currentFinancialInstruments2022-10-0514402511dpl:CostSales2022-10-062023-03-3114402511dpl:DistributionCosts2022-10-062023-03-3114402511dpl:AdministrativeExpenses2022-10-062023-03-3114402511core:LandBuildings2022-10-062023-03-3114402511core:PlantMachinery2022-10-062023-03-3114402511core:Vehicles2022-10-062023-03-3114402511core:FurnitureFittings2022-10-062023-03-3114402511core:OfficeEquipment2022-10-062023-03-3114402511core:NetGoodwill2022-10-062023-03-3114402511core:IntangibleAssetsOtherThanGoodwill2022-10-062023-03-3114402511dpl:GroupUndertakings2022-10-062023-03-3114402511dpl:ParticipatingInterests2022-10-062023-03-3114402511dpl:GroupUndertakingscore:ListedExchangeTraded2022-10-062023-03-3114402511core:ListedExchangeTraded2022-10-062023-03-3114402511dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-10-062023-03-3114402511core:UnlistedNon-exchangeTraded2022-10-062023-03-3114402511dpl:CostSales2022-10-052022-10-0514402511dpl:DistributionCosts2022-10-052022-10-0514402511dpl:AdministrativeExpenses2022-10-052022-10-0514402511core:LandBuildings2022-10-052022-10-0514402511core:PlantMachinery2022-10-052022-10-0514402511core:Vehicles2022-10-052022-10-0514402511core:FurnitureFittings2022-10-052022-10-0514402511core:OfficeEquipment2022-10-052022-10-0514402511core:NetGoodwill2022-10-052022-10-0514402511core:IntangibleAssetsOtherThanGoodwill2022-10-052022-10-0514402511dpl:GroupUndertakings2022-10-052022-10-0514402511dpl:ParticipatingInterests2022-10-052022-10-0514402511dpl:GroupUndertakingscore:ListedExchangeTraded2022-10-052022-10-0514402511core:ListedExchangeTraded2022-10-052022-10-0514402511dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-10-052022-10-0514402511core:UnlistedNon-exchangeTraded2022-10-052022-10-0514402511core:NetGoodwill2023-03-3114402511core:IntangibleAssetsOtherThanGoodwill2023-03-3114402511core:LandBuildings2023-03-3114402511core:PlantMachinery2023-03-3114402511core:Vehicles2023-03-3114402511core:FurnitureFittings2023-03-3114402511core:OfficeEquipment2023-03-3114402511core:AfterOneYear2023-03-3114402511core:WithinOneYear2023-03-3114402511core:ListedExchangeTraded2023-03-3114402511core:UnlistedNon-exchangeTraded2023-03-3114402511core:ShareCapital2023-03-3114402511core:SharePremium2023-03-3114402511core:RevaluationReserve2023-03-3114402511core:OtherReservesSubtotal2023-03-3114402511core:RetainedEarningsAccumulatedLosses2023-03-3114402511core:NetGoodwill2022-10-0514402511core:IntangibleAssetsOtherThanGoodwill2022-10-0514402511core:LandBuildings2022-10-0514402511core:PlantMachinery2022-10-0514402511core:Vehicles2022-10-0514402511core:FurnitureFittings2022-10-0514402511core:OfficeEquipment2022-10-0514402511core:AfterOneYear2022-10-0514402511core:WithinOneYear2022-10-0514402511core:ListedExchangeTraded2022-10-0514402511core:UnlistedNon-exchangeTraded2022-10-0514402511core:ShareCapital2022-10-0514402511core:SharePremium2022-10-0514402511core:RevaluationReserve2022-10-0514402511core:OtherReservesSubtotal2022-10-0514402511core:RetainedEarningsAccumulatedLosses2022-10-0514402511core:NetGoodwill2022-10-0514402511core:IntangibleAssetsOtherThanGoodwill2022-10-0514402511core:LandBuildings2022-10-0514402511core:PlantMachinery2022-10-0514402511core:Vehicles2022-10-0514402511core:FurnitureFittings2022-10-0514402511core:OfficeEquipment2022-10-0514402511core:AfterOneYear2022-10-0514402511core:WithinOneYear2022-10-0514402511core:ListedExchangeTraded2022-10-0514402511core:UnlistedNon-exchangeTraded2022-10-0514402511core:ShareCapital2022-10-0514402511core:SharePremium2022-10-0514402511core:RevaluationReserve2022-10-0514402511core:OtherReservesSubtotal2022-10-0514402511core:RetainedEarningsAccumulatedLosses2022-10-0514402511core:AfterOneYear2022-10-062023-03-3114402511core:WithinOneYear2022-10-062023-03-3114402511core:Non-currentFinancialInstrumentscore:CostValuation2022-10-062023-03-3114402511core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-10-062023-03-3114402511core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-10-062023-03-3114402511core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-10-062023-03-3114402511core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-10-062023-03-3114402511core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-10-062023-03-3114402511core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-10-062023-03-3114402511core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-10-062023-03-3114402511core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-10-062023-03-3114402511core:Non-currentFinancialInstrumentscore:CostValuation2023-03-3114402511core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-03-3114402511core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-03-3114402511core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-03-3114402511core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-03-3114402511core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-03-3114402511core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-03-3114402511core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-03-3114402511core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-03-3114402511core:Non-currentFinancialInstrumentscore:CostValuation2022-10-0514402511core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-10-0514402511core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-10-0514402511core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-10-0514402511core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-10-0514402511core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-10-0514402511core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-10-0514402511core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-10-0514402511core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-10-0514402511bus:Director12022-10-062023-03-31

CHRISTA GDP PHARMA LTD

Registered Number
14402511
(England and Wales)

Unaudited Financial Statements for the Period ended
31 March 2023

CHRISTA GDP PHARMA LTD
Company Information
for the period from 6 October 2022 to 31 March 2023

Director

MARTIN, Christopher Thomas

Registered Address

35 St. Leonards Road
Northampton
NN4 8DL

Registered Number

14402511 (England and Wales)
CHRISTA GDP PHARMA LTD
Balance Sheet as at
31 March 2023

Notes

2023

£

£

Fixed assets
Tangible assets5805
805
Current assets
Debtors62,390
Cash at bank and on hand7,104
9,494
Creditors amounts falling due within one year7(4,460)
Net current assets (liabilities)5,034
Total assets less current liabilities5,839
Net assets5,839
Capital and reserves
Called up share capital100
Profit and loss account5,739
Shareholders' funds5,839
The financial statements were approved and authorised for issue by the Director on 12 July 2023, and are signed on its behalf by:
MARTIN, Christopher Thomas
Director
Registered Company No. 14402511
CHRISTA GDP PHARMA LTD
Notes to the Financial Statements
for the period ended 31 March 2023

1.Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
2.Compliance with applicable reporting framework
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
3.Accounting policies
Property, plant and equipment policy
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Straight line (years)
Plant and machinery3
Office Equipment3
Revenue recognition policy
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Foreign currency translation and operations policy
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
4.Employee information

2023
Average number of employees during the year1
5.Property, plant and equipment

Office Equipment

Total

££
Cost or valuation
Additions930930
At 31 March 23930930
Depreciation and impairment
Charge for year125125
At 31 March 23125125
Net book value
At 31 March 23805805
At 05 October 22--
6.Debtors

2023

£
Trade debtors / trade receivables2,390
Total2,390
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
7.Creditors within one year

2023

£
Taxation and social security3,848
Other creditors612
Total4,460
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.